The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms

Leuk Lymphoma. 2017 Aug;58(8):1914-1921. doi: 10.1080/10428194.2016.1262032. Epub 2016 Dec 2.

Abstract

Gene expression profiling in Philadelphia-negative chronic myeloproliferative neoplasms (MPNs) have unraveled significant deregulation of several immune and inflammation genes of potential importance for clonal evolution. Other mechanisms might be downregulation of major histocompatibility class I and II genes used by tumor cells to escape antitumor T-cell-mediated immune responses. Several genes encoding human leukocyte antigen (HLA) class I and II molecules have been shown to be significantly downregulated. Upregulation of HLA genes is considered one of the mechanisms of action of interferon (IFN)-alpha2, but regulation of these genes during IFN-alpha2 treatment in MPNs has never been studied. Our findings show a significant upregulation of several HLA genes of importance for tumor immune surveillance by IFN-alpha2 treatment in MPNs. This mechanism might enhance the cytotoxic potential of immune cells against MPNs and explain the induction of minimal residual disease by IFN-alpha2 treatment in these patients.

Keywords: HLA genes; Interferon-alpha2; myeloproliferative neoplasms; tumor immune surveillance; whole blood transcriptional profiling.

MeSH terms

  • Alleles
  • Gene Expression Profiling
  • Gene Expression Regulation / drug effects*
  • HLA Antigens / genetics*
  • Humans
  • Interferon-alpha / pharmacology*
  • Interferon-alpha / therapeutic use
  • Myeloproliferative Disorders / drug therapy
  • Myeloproliferative Disorders / genetics*
  • Polycythemia Vera / drug therapy
  • Polycythemia Vera / genetics*
  • Primary Myelofibrosis / drug therapy
  • Primary Myelofibrosis / genetics
  • Thrombocythemia, Essential / drug therapy
  • Thrombocythemia, Essential / genetics

Substances

  • HLA Antigens
  • Interferon-alpha